Posts Tagged: liquid biopsy

Liquid biopsy to detect tumor DNA: The possibilities

An article published on WBUR’s CommonHealth blog opens a window into liquid biopsy, also referred to as blood biopsy, in its current and future state. The article discusses how this rapidly-evolving technology has the potential to transform the way we detect and treat cancer. The technology of liquid biopsy is rapidly evolving, but still has… Read article →


QIAGEN at AMP Global 2017

The inaugural AMP Global Congress on Molecular Pathology, hosted by the Association for Medical Pathologists (AMP), is the event of the year for molecular pathology, diagnostic technologies and research and clinical applications. AMP Global 2017 is the perfect event for QIAGEN to remind and educate the market about our broad menu of Sample to Insight… Read article →


Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →


Leading Innovation in Biomarker Testing: Liquid Biopsy

Cutting edge approaches which use techniques such as liquid biopsy are the future of biomarker testing, but require expertise and leadership to develop. QIAGEN’s companion diagnostic assays are designed to ease the challenges faced by pathologists in labs performing the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to… Read article →


QIAGEN’s NGS solutions highlighted at the annual Congress of the European Society of Pathology

QIAGEN’s broad portfolio of Sample to Insight solutions for NGS were a focus at the QIAGEN booth and industry symposium at this year’s annual Congress of the European Society of Pathology. The XXXI International Congress of the International Academy of Pathology (IAP) and 28th Congress of the European Society of Pathology (ESP) was hosted for… Read article →


Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →